Recursion Pharmaceuticals Inc Class A RXRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMAR, PANL, BALY, RXRX on Behalf of Shareholders
-
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
-
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXRX, GVP, OBDE, OBDC on Behalf of Shareholders
-
Kuehn Law Encourages ITI, RXRX, GVP, and OBDE Investors to Contact Law Firm
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXRX, GVP, OBDE on Behalf of Shareholders
-
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
Trading Information
- Previous Close Price
- $6.06
- Day Range
- $6.07–6.34
- 52-Week Range
- $4.97–15.74
- Bid/Ask
- $6.09 / $6.14
- Market Cap
- $1.72 Bil
- Volume/Avg
- 3.8 Mil / 5.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 28.41
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 500
- Website
- https://www.recursion.com
Comparables
Valuation
|
Metric
|
RXRX
|
301080
|
02509
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 50.16 | — |
Price/Book Value | 2.91 | 2.00 | 32.68 |
Price/Sales | 28.41 | 8.82 | 100.25 |
Price/Cash Flow | — | 25.12 | — |
Price/Earnings
RXRX
301080
02509
Financial Strength
|
Metric
|
RXRX
|
301080
|
02509
|
|---|---|---|---|
Quick Ratio | 5.54 | 6.52 | 1.70 |
Current Ratio | 6.07 | 7.21 | 1.86 |
Interest Coverage | −852.98 | 20.16 | −18.42 |
Quick Ratio
RXRX
301080
02509
Profitability
|
Metric
|
RXRX
|
301080
|
02509
|
|---|---|---|---|
Return on Assets (Normalized) | −47.23% | 3.85% | −47.40% |
Return on Equity (Normalized) | −65.86% | 4.21% | −341.08% |
Return on Invested Capital (Normalized) | −61.55% | 1.82% | −56.34% |
Return on Assets
RXRX
301080
02509
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Xwfrgjbdtt | Drmb | $516.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jdghrhk | Hyslsl | $117.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dymzpntlh | Pyvtpf | $111.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dxbrhjm | Tmgqkqd | $34.6 Bil | |||
| argenx SE ADR
ARGX
| Mqbyyybc | Mkn | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Hkzkcjgv | Qbzq | $28.5 Bil | |||
| Moderna Inc
MRNA
| Mbwhrdc | Sflqy | $23.5 Bil | |||
| United Therapeutics Corp
UTHR
| Mkkrvql | Gbjf | $15.6 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Pzzjcyvtq | Qkmkcs | $13.0 Bil | |||
| Incyte Corp
INCY
| Zmvfxmhmr | Pvhch | $12.9 Bil |
United States